Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2− locally advanced or metastatic breast cancer: a Brazilian private payer perspective

BACKGROUND: The global burden of breast cancer (BC) is high, especially in advanced stages. CDK 4/6 inhibitors represent a paradigm shift in the treatment of advanced BC HR+/HER2−, given the clinically and statistically significant gain in overall survival associated with this new class of medicatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Buehler, Anna Maria, Castilho, Gabriela, Dionne, Pierre-Alexandre, Stefani, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053836/
https://www.ncbi.nlm.nih.gov/pubmed/33948121
http://dx.doi.org/10.1177/17588359211000593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053836/
https://www.ncbi.nlm.nih.gov/pubmed/33948121
http://dx.doi.org/10.1177/17588359211000593

Ejemplares similares